Glynase Prestab
- Generic Name: micronized glyburide tablets
- Brand Name: Glynase PresTab
Glynase PresTab (Micronized Glyburide Tablets) side effects drug center
Glynase Prestab Side Effects Center
Glynase PresTab (micronized glyburide) is an oral blood-glucose-lowering drug used to treat type 2 diabetes (non-insulin dependent). It is not for treating type 1 diabetes. Glynase PresTab is available in generic form. Common side effects of Glynase PresTab include nausea, heartburn, feeling full, joint or muscle pain, blurred vision, itching or skin rash. Tell your doctor if you have serious side effects of Glynase PresTab including fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of skin or eyes), confusion, easy bruising or bleeding, hallucinations, fainting, or shallow breathing.
The suggested starting dose of Glynase PresTab is 1.5 to 3 mg daily, administered with breakfast or the first main meal. Glynase PresTab may interact with blood thinners, cyclosporine, disopyramide, fluconazole, ketoconazole, fluoxetine, rifampin, ACE inhibitors, antibiotics, albuterol, clonidine, reserpine, or beta-blockers. Hyperglycemia (high blood sugar) may result if you take Glynase with: isoniazid, diuretics, steroids, phenothiazines, thyroid medicines, birth control pills and other hormones, heart or blood pressure medications, seizure medicines, and diet pills or medicines to treat asthma, colds or allergies. Hypoglycemia (low blood sugar) may result if you take Glynase with: clarithromycin, exenatide, probenecid, heart or blood pressure medications, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates, sulfa drugs, monoamine oxidase inhibitors (MAOIs), or other oral diabetes medications. Tell your doctor all medications and supplements you use. During pregnancy, Glynase PresTab should be used only if prescribed. It is unknown if this drug will harm a fetus. Similar diabetes medications can cause severe hypoglycemia in newborn babies whose mothers used the medication near the time of delivery. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.
Our Glynase PresTab (micronized glyburide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Glynase Prestab Consumer Information
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).
Call your doctor at once if you have:
- dark urine, jaundice (yellowing of the skin or eyes);
- severe skin rash, redness, or itching;
- pale skin, easy bruising or bleeding;
- fever, chills, sore throat, mouth sores; or
- low levels of sodium in the body--headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady.
Older adults may be more likely to have low blood sugar while taking glyburide.
Common side effects may include:
- low blood sugar;
- nausea, heartburn, feeling full;
- muscle or joint pain;
- blurred vision; or
- mild rash or skin redness.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Glynase Prestab (Micronized Glyburide Tablets)
Glynase Prestab Professional Information
SIDE EFFECTS
Hypoglycemia
See PRECAUTIONS and OVERDOSAGE Sections.
Gastrointestinal Reactions
Cholestatic jaundice and hepatitis may occur rarely which may progress to liver failure; GLYNASE PresTab Tablets should be discontinued if this occurs.
Liver function abnormalities, including isolated transaminase elevations, have been reported.
Gastrointestinal disturbances, eg, nausea, epigastric fullness, and heartburn are the most common reactions, having occurred in 1.8% of treated patients during clinical trials. They tend to be dose related and may disappear when dosage is reduced.
Dermatologic Reactions
Allergic skin reactions, eg, pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions occurred in 1.5% of treated patients during clinical trials. These may be transient and may disappear despite continued use of glyburide. If skin reactions persist, the drug should be discontinued.
Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.
Hematologic Reactions
Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia (see PRECAUTIONS), aplastic anemia, and pancytopenia have been reported with sulfonylureas.
Metabolic Reactions
Hepatic porphyria and disulfiram-like reactions have been reported with sulfonylureas; however, hepatic porphyria has not been reported with glyburide and disulfiram-like reactions have been reported very rarely.
Cases of hyponatremia have been reported with glyburide and all other sulfonylureas, most often in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain other sulfonylureas, and it has been suggested that these sulfonylureas may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.
Other Reactions
Changes in accommodation and/or blurred vision have been reported with glyburide and other sulfonylureas. These are thought to be related to fluctuation in glucose levels.
In addition to dermatologic reactions, allergic reactions such as angioedema, arthralgia, myalgia and vasculitis have been reported.
Read the entire FDA prescribing information for Glynase Prestab (Micronized Glyburide Tablets)
&Copy; Glynase Prestab Patient Information is supplied by Cerner Multum, Inc. and Glynase Prestab Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.